It seems as if 2022 is shaping up to be a big year for Diabetes Tech. Several deals, strong data, and product approvals are making the space red hot right now.
Glooko is the latest newsmaker for diabetes tech – as the Palo Alto, CA-based company is quickly hopping back on the M&A trail after the xBird deal in February.
Glooko has acquired Diabnext, a company whose digital health platform helps people with diabetes better manage their conditions and connects to their healthcare providers, so they can work together to improve health outcomes.
Diabnext, which is based in France, would help expand Glooko’s offerings in Europe.
Diabnext’s mobile app complements Glooko's product portfolio Under the Glooko product umbrella, Diabnext’s technology can significantly increase the number of patients and healthcare providers in the territory and expand remote patient monitoring offerings.
“The addition of Diabnext expands our offerings with a unique platform that can help us better customize the patient experience and improve health outcomes for people with diabetes,” said Russ Johannesson, CEO of Glooko. “Glooko's acquisition of Diabnext further cements our commitment to increase our global presence and continue to drive innovative solutions."
The company said the Diabnext platform will be marketed under the name Glooko XT.
The Diabnext deal comes at a time when there are major developments occurring in the diabetes management space. In the last few months two of the most anticipated devices in the space won approval.
And earlier this week, Better Therapeutics announced favorable primary endpoint data from the pivotal trial of BT-001, the company’s investigational prescription digital therapeutic platform.